Ralph A DeFronzo Selected Research

acipimox

3/2016	Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
3/2007	Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration.
9/2004	Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ralph A DeFronzo Research Topics

Disease

125	Type 2 Diabetes Mellitus (MODY) 01/2022 - 02/2002
113	Insulin Resistance 01/2022 - 03/2002
33	Glucose Intolerance 01/2021 - 01/2003
25	Hyperglycemia 01/2022 - 11/2002
16	Obesity 01/2022 - 01/2004
14	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 05/2005
13	Prediabetic State (Prediabetes) 01/2022 - 06/2009
12	Weight Gain 01/2021 - 05/2005
10	Body Weight (Weight, Body) 01/2021 - 06/2003
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 11/2006
10	Weight Loss (Weight Reduction) 10/2018 - 05/2005
8	Inflammation (Inflammations) 01/2021 - 04/2007
8	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 07/2006
6	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 04/2007
5	Hyperinsulinism (Hyperinsulinemia) 01/2022 - 02/2005
5	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2011
4	Dyslipidemias (Dyslipidemia) 01/2022 - 04/2007
4	Hypertension (High Blood Pressure) 01/2022 - 01/2018
4	Myocardial Infarction 01/2020 - 08/2011
4	Atherosclerosis 12/2019 - 02/2005
4	Stroke (Strokes) 01/2017 - 05/2006
3	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2018 - 05/2011
2	Fibrosis (Cirrhosis) 01/2022 - 01/2011
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 06/2016
2	Glycosuria 01/2020 - 09/2008
2	Ketosis 01/2020 - 01/2019
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2019 - 06/2016
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018 - 05/2006
2	Chronic Kidney Failure (Chronic Renal Failure) 10/2017 - 05/2003
2	Heart Failure 05/2016 - 05/2006
2	Overweight 08/2015 - 04/2009
2	Disease Progression 05/2014 - 03/2010
2	Diabetes Mellitus 08/2011 - 07/2003
2	Edema (Dropsy) 03/2011 - 05/2006
2	Metabolic Diseases (Metabolic Disease) 06/2008 - 02/2007

Drug/Important Bio-Agent (IBA)

115	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 02/2002
89	Insulin (Novolin)FDA Link 01/2022 - 02/2002
32	Pioglitazone (Actos)FDA Link 01/2022 - 03/2002
22	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 05/2005
17	LipidsIBA 01/2022 - 05/2003
16	Exenatide (Byetta)FDA Link 01/2022 - 05/2005
15	Nonesterified Fatty Acids (NEFA)IBA 01/2017 - 08/2002
12	AdiponectinIBA 01/2021 - 01/2004
12	empagliflozinIBA 07/2018 - 03/2015
11	Triglycerides (Triacylglycerol)IBA 01/2022 - 05/2006
11	C-PeptideIBA 01/2021 - 01/2005
9	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 09/2008
9	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 08/2005
9	Glucagon (Glukagon)FDA Link 01/2021 - 05/2006
8	Pharmaceutical PreparationsIBA 01/2022 - 02/2007
8	dapagliflozinIBA 01/2022 - 08/2013
8	HDL CholesterolIBA 01/2021 - 05/2006
8	IncretinsIBA 08/2016 - 05/2005
7	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2017 - 05/2006
6	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2010
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2006
6	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2021 - 07/2013
6	Sodium-Glucose Transport ProteinsIBA 08/2016 - 09/2008
5	SodiumIBA 01/2022 - 06/2016
5	Adenosine Triphosphate (ATP)IBA 01/2021 - 09/2008
5	EnzymesIBA 01/2021 - 07/2006
5	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 05/2015
5	LinagliptinIBA 07/2018 - 03/2015
4	Blood Glucose (Blood Sugar)IBA 01/2021 - 03/2010
4	GlycogenIBA 12/2018 - 02/2002
4	ThiazolidinedionesIBA 03/2007 - 08/2003
3	Arginine (L-Arginine)FDA Link 01/2021 - 01/2008
3	Glucagon-Like Peptide-1 ReceptorIBA 12/2020 - 05/2006
3	2,4-thiazolidinedione (thiazolidinedione)IBA 12/2020 - 01/2004
3	KetonesIBA 01/2019 - 11/2016
3	Hemoglobins (Hemoglobin)IBA 12/2018 - 04/2007
3	Liraglutide FDA Link 01/2018 - 08/2015
3	AdipokinesIBA 12/2016 - 09/2004
3	acipimoxIBA 03/2016 - 09/2004
2	CarbohydratesIBA 01/2022 - 11/2006
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2011
2	Insulin ReceptorIBA 01/2021 - 05/2014
2	CeramidesIBA 01/2021 - 01/2004
2	Carotenoids (Carotene)IBA 01/2021 - 07/2017
2	Drug CombinationsIBA 01/2020 - 09/2015
2	omega-Chloroacetophenone (Mace)IBA 01/2020 - 01/2017
2	Sitagliptin Phosphate (Januvia)FDA Link 04/2018 - 09/2013
2	Small Interfering RNA (siRNA)IBA 01/2018 - 05/2015
2	CreatinineIBA 10/2017 - 05/2003
2	HDL LipoproteinsIBA 07/2017 - 04/2007
2	Streptozocin (Streptozotocin)FDA Link 08/2015 - 12/2012
2	PalmitatesIBA 05/2015 - 11/2014
2	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2015 - 08/2011
2	Neurotransmitter Agents (Neurotransmitter)IBA 05/2014 - 03/2010
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 08/2013 - 05/2006
2	alogliptinIBA 09/2010 - 12/2008
2	Rosiglitazone (Avandia)FDA Link 05/2010 - 11/2006
2	Hemoglobin AIBA 03/2010 - 11/2002
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2008 - 11/2006
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2006 - 01/2003
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	fibroblast growth factor 21IBA 01/2022

Therapy/Procedure

40	Therapeutics 01/2022 - 02/2002
20	Glycemic Control 04/2018 - 03/2002
3	Drug Therapy (Chemotherapy) 11/2021 - 10/2014